Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2026 | $15.00 | Buy | Truist |
| 2/5/2026 | $38.00 | Buy | BofA Securities |
| 12/12/2025 | $20.00 → $33.00 | Outperform | Wedbush |
| 12/9/2025 | $27.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 10/20/2025 | $18.00 | Overweight | Wells Fargo |
| 8/4/2025 | $19.00 | Buy | Canaccord Genuity |
| 7/28/2025 | $24.00 | Outperform | Oppenheimer |
| 7/16/2025 | $16.00 | Buy | Citigroup |
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
SCHEDULE 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
DEF 14A - Wave Life Sciences Ltd. (0001631574) (Filer)
Truist resumed coverage of Wave Life Sciences with a rating of Buy and set a new price target of $15.00
BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00
Wedbush reiterated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $33.00 from $20.00 previously
3 - Wave Life Sciences Ltd. (0001631574) (Issuer)
3 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
TAIPEI, Taiwan, June 2, 2026 /PRNewswire/ -- Eco Wave Power Global AB (publ) (NASDAQ:WAVE), a leading onshore wave energy technology company, today announced that its technology was featured for the second time in an NVIDIA GTC keynote presentation, this time during NVIDIA Founder and CEO Jensen Huang's GTC Taipei 2026 keynote, highlighting the growing role of digital twins and simulation technologies in the optimization of real-world infrastructure. The latest appearance follows Eco Wave Power's inclusion in NVIDIA's GTC San Jose keynote presentation in March 2026, marking the
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in June. 2026 Jefferies Global Healthcare ConferenceDate: Wednesday, June 3, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Monday, June 8, 2026 Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., May 19, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Wave Life Sciences as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On track for feedback from FDA on potential accelerated approval pathway mid-2026 WVE-006 generated wild-type M-AAT comprising 64% of total AAT and reduced harmful Z-AAT by 71%, with 11.9 µM total AAT in the 200 mg biweekly cohort; effects were consistent with 400 mg monthly dosing regimen, with 13.6 µM total AAT; editing was sustained at least three months following last dose Restored dynamic AAT production with two new observations of elevated AAT during acute phase responses
With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026 Combination and maintenance trials of WVE-007 on track to initiate in 2026 Data from RestorAATion-2 trial of WVE-006 (GalNAc-RNA editing) in AATD (including 400 mg monthly dose and 600 mg single dose cohorts) to be presented at an investor webcast during the ATS International Conference in May 2026 Regulatory feedback on accelerated approval pathway for WVE-006 continues to be expected mid-2026 CTA submission for WVE-008 (GalNAc-RNA editing for PNPLA
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company's first quarter 2026 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call a
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)